# Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-two-upcoming-investor-conferences-e077827c
Ticker: SGMT
Company: Sagimet Biosciences
Source: Sagimet Biosciences
Published: 2026-09-02 11:00 EST
## Summary

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing...

## Article Body
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

Cantor 2026 Global Healthcare Conference in New York, NY on Wednesday, September 9, 2026, with a fireside chat at 1.35pm ET (link here ).

H.C. Wainwright 28 th Annual Global Investment Conference in New York, NY on Monday, September 14, 2026.

The fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com , with an archived replay available for 90 days following the live event.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com .

Investor Contact: Joyce Allaire LifeSci Advisors JAllaire@LifeSciAdvisors.com

Media Contact: Maggie Whitney LifeSci Communications mwhitney@lifescicomms.com
## Recent Company News
- 2026-09-02 11:00 EST — [Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-participation-in-two-upcoming-investor-conferences-e077827c) — Source: Sagimet Biosciences
- 2026-08-25 11:00 EST — [Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-tow-626dcbba) — Source: Sagimet Biosciences
- 2026-08-17 20:28 EST — [Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635-c--05c1f350) — Source: Sagimet Biosciences
- 2026-08-13 11:00 EST — [Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-receives-fda-study-may-proceed-letter-and-ind-clearance-for--0441dcad) — Source: Sagimet Biosciences
- 2026-08-11 11:30 EST — [Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/SGMT/sagimet-biosciences-reports-second-quarter-2026-financial-results-and-provides-c-17b8cabc) — Source: Sagimet Biosciences
## Related News
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)
- 2026-09-04 20:05 EST — LIXT — [NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS](https://biopharmsignal.com/news/LIXT/nomad-power-solutions-announces-adjournment-of-special-meeting-of-stockholders-74cd9e2e)
- 2026-09-04 20:05 EST — AVTX — [Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-announces-inducement-grants-to-new-employees-under-nasdaq-lis-cc7baaf2)
- 2026-09-04 20:05 EST — NTLA — [Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/NTLA/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-250d5dd9)